Cargando…

Elevated Serum Lactate Dehydrogenase Predicts Unfavorable Outcomes After rt-PA Thrombolysis in Ischemic Stroke Patients

BACKGROUND AND PURPOSE: Currently, acute ischemic stroke (AIS) is one of the most common and serious diseases in the world and is associated with very high mortality and morbidity even after thrombolysis therapy. This study aims to research the relationship between lactic dehydrogenase (LDH) and pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Huijuan, Bi, Rentang, Hu, Jichuan, Xu, Da, Su, Ying, Huang, Ming, Peng, Qiwei, Li, Zhifang, Chen, Shengcai, Hu, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019114/
https://www.ncbi.nlm.nih.gov/pubmed/35463134
http://dx.doi.org/10.3389/fneur.2022.816216
_version_ 1784689180207480832
author Jin, Huijuan
Bi, Rentang
Hu, Jichuan
Xu, Da
Su, Ying
Huang, Ming
Peng, Qiwei
Li, Zhifang
Chen, Shengcai
Hu, Bo
author_facet Jin, Huijuan
Bi, Rentang
Hu, Jichuan
Xu, Da
Su, Ying
Huang, Ming
Peng, Qiwei
Li, Zhifang
Chen, Shengcai
Hu, Bo
author_sort Jin, Huijuan
collection PubMed
description BACKGROUND AND PURPOSE: Currently, acute ischemic stroke (AIS) is one of the most common and serious diseases in the world and is associated with very high mortality and morbidity even after thrombolysis therapy. This study aims to research the relationship between lactic dehydrogenase (LDH) and prognosis in AIS patients treated with intravenous rtPA. METHOD: This study (a Multicenter Clinical Trial of Revascularization Treatment for Acute Ischemic Stroke, TRAIS) included 527 AIS patients in 5 cooperative medical institutions in China from January 2018 to February 2021. The primary outcome was major disability and death within 3 months (mRS score of 3–6), and the secondary outcomes were early neurological improvement (ENI), early neurological deterioration (END), moderate-severe cerebral edema (CE), and symptomatic intracranial hemorrhage (sICH). RESULTS: The mean age of the 527 patients was 65.6 ± 11.7 years, and the median baseline NIHSS score was 4 (interquartile range, 2–7). The median serum LDH level was 184 U/L (interquartile range, 163–212 U/L). In total, 287 (54.5%) patients acquired ENI, 68 (13.0%) patients suffered END, 53 (12.1%) patients were observed with moderate-severe CE, and 28 (6.2%) patients showed sICH. Within 3 months, 127 (25.15%) patients experienced the primary outcome and 42 (8.3%) patients died. Serum LDH levels before thrombolysis showed an independent association with the risk of primary outcome [adjusted odds ratio, 3.787; (95% CI, 1.525–9.404); P = 0.014]. When log-transformed LDH increased each standard deviation, the risk of primary outcome was raised by 80.1% (95% CI, 28.9–251.7%). A positive linear dependence between the risk of primary outcome and serum LDH levels (P of linearity = 0.0248, P of non-linearity = 0.8284) was shown in multivariable-adjusted spline regression models. Pre-thrombolysis LDH quartile also provided a conventional risk model and significant improvement of the prediction for clinical outcomes, with a net reclassification improvement index (NRI) = 41.86% (P < 0.001) and integrated discrimination improvement (IDI) = 4.68% (P < 0.001). CONCLUSIONS: Elevated serum LDH levels predicted unfavorable clinical outcomes after intravenous thrombolysis in AIS patients.
format Online
Article
Text
id pubmed-9019114
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90191142022-04-21 Elevated Serum Lactate Dehydrogenase Predicts Unfavorable Outcomes After rt-PA Thrombolysis in Ischemic Stroke Patients Jin, Huijuan Bi, Rentang Hu, Jichuan Xu, Da Su, Ying Huang, Ming Peng, Qiwei Li, Zhifang Chen, Shengcai Hu, Bo Front Neurol Neurology BACKGROUND AND PURPOSE: Currently, acute ischemic stroke (AIS) is one of the most common and serious diseases in the world and is associated with very high mortality and morbidity even after thrombolysis therapy. This study aims to research the relationship between lactic dehydrogenase (LDH) and prognosis in AIS patients treated with intravenous rtPA. METHOD: This study (a Multicenter Clinical Trial of Revascularization Treatment for Acute Ischemic Stroke, TRAIS) included 527 AIS patients in 5 cooperative medical institutions in China from January 2018 to February 2021. The primary outcome was major disability and death within 3 months (mRS score of 3–6), and the secondary outcomes were early neurological improvement (ENI), early neurological deterioration (END), moderate-severe cerebral edema (CE), and symptomatic intracranial hemorrhage (sICH). RESULTS: The mean age of the 527 patients was 65.6 ± 11.7 years, and the median baseline NIHSS score was 4 (interquartile range, 2–7). The median serum LDH level was 184 U/L (interquartile range, 163–212 U/L). In total, 287 (54.5%) patients acquired ENI, 68 (13.0%) patients suffered END, 53 (12.1%) patients were observed with moderate-severe CE, and 28 (6.2%) patients showed sICH. Within 3 months, 127 (25.15%) patients experienced the primary outcome and 42 (8.3%) patients died. Serum LDH levels before thrombolysis showed an independent association with the risk of primary outcome [adjusted odds ratio, 3.787; (95% CI, 1.525–9.404); P = 0.014]. When log-transformed LDH increased each standard deviation, the risk of primary outcome was raised by 80.1% (95% CI, 28.9–251.7%). A positive linear dependence between the risk of primary outcome and serum LDH levels (P of linearity = 0.0248, P of non-linearity = 0.8284) was shown in multivariable-adjusted spline regression models. Pre-thrombolysis LDH quartile also provided a conventional risk model and significant improvement of the prediction for clinical outcomes, with a net reclassification improvement index (NRI) = 41.86% (P < 0.001) and integrated discrimination improvement (IDI) = 4.68% (P < 0.001). CONCLUSIONS: Elevated serum LDH levels predicted unfavorable clinical outcomes after intravenous thrombolysis in AIS patients. Frontiers Media S.A. 2022-04-06 /pmc/articles/PMC9019114/ /pubmed/35463134 http://dx.doi.org/10.3389/fneur.2022.816216 Text en Copyright © 2022 Jin, Bi, Hu, Xu, Su, Huang, Peng, Li, Chen and Hu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Jin, Huijuan
Bi, Rentang
Hu, Jichuan
Xu, Da
Su, Ying
Huang, Ming
Peng, Qiwei
Li, Zhifang
Chen, Shengcai
Hu, Bo
Elevated Serum Lactate Dehydrogenase Predicts Unfavorable Outcomes After rt-PA Thrombolysis in Ischemic Stroke Patients
title Elevated Serum Lactate Dehydrogenase Predicts Unfavorable Outcomes After rt-PA Thrombolysis in Ischemic Stroke Patients
title_full Elevated Serum Lactate Dehydrogenase Predicts Unfavorable Outcomes After rt-PA Thrombolysis in Ischemic Stroke Patients
title_fullStr Elevated Serum Lactate Dehydrogenase Predicts Unfavorable Outcomes After rt-PA Thrombolysis in Ischemic Stroke Patients
title_full_unstemmed Elevated Serum Lactate Dehydrogenase Predicts Unfavorable Outcomes After rt-PA Thrombolysis in Ischemic Stroke Patients
title_short Elevated Serum Lactate Dehydrogenase Predicts Unfavorable Outcomes After rt-PA Thrombolysis in Ischemic Stroke Patients
title_sort elevated serum lactate dehydrogenase predicts unfavorable outcomes after rt-pa thrombolysis in ischemic stroke patients
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019114/
https://www.ncbi.nlm.nih.gov/pubmed/35463134
http://dx.doi.org/10.3389/fneur.2022.816216
work_keys_str_mv AT jinhuijuan elevatedserumlactatedehydrogenasepredictsunfavorableoutcomesafterrtpathrombolysisinischemicstrokepatients
AT birentang elevatedserumlactatedehydrogenasepredictsunfavorableoutcomesafterrtpathrombolysisinischemicstrokepatients
AT hujichuan elevatedserumlactatedehydrogenasepredictsunfavorableoutcomesafterrtpathrombolysisinischemicstrokepatients
AT xuda elevatedserumlactatedehydrogenasepredictsunfavorableoutcomesafterrtpathrombolysisinischemicstrokepatients
AT suying elevatedserumlactatedehydrogenasepredictsunfavorableoutcomesafterrtpathrombolysisinischemicstrokepatients
AT huangming elevatedserumlactatedehydrogenasepredictsunfavorableoutcomesafterrtpathrombolysisinischemicstrokepatients
AT pengqiwei elevatedserumlactatedehydrogenasepredictsunfavorableoutcomesafterrtpathrombolysisinischemicstrokepatients
AT lizhifang elevatedserumlactatedehydrogenasepredictsunfavorableoutcomesafterrtpathrombolysisinischemicstrokepatients
AT chenshengcai elevatedserumlactatedehydrogenasepredictsunfavorableoutcomesafterrtpathrombolysisinischemicstrokepatients
AT hubo elevatedserumlactatedehydrogenasepredictsunfavorableoutcomesafterrtpathrombolysisinischemicstrokepatients